A New Perspective on Cerebral Blood Vessels, NeuFlow
We provide accurate diagnostics with the world's first 3D color MRA technology.
Experience a personalized brain health guide powered by our FDA-approved, proprietary algorithm solution.
We provide accurate diagnostics with the world's first 3D color MRA technology.
Experience a personalized brain health guide powered by our FDA-approved, proprietary algorithm solution.
We provide accurate diagnostics with the world's first 3D color MRA technology.
Experience a personalized brain health guide powered by our FDA-approved, proprietary algorithm solution.
A groundbreaking medical technology that transforms 2D black-and-white MRA into 3D color analysis supported by quantitative data.
A next-generation brain vessel analysis solution integrating the advantages of both CFD and PC-MR technologies.
Quick and convenient detection of major cerebrovascular risk factors, including cerebral infarction, stroke, and aneurysms.
A groundbreaking medical technology that transforms 2D black-and-white MRA into 3D color analysis supported by quantitative data.
A next-generation brain vessel analysis solution integrating the advantages of both CFD and PC-MR technologies.
Quick and convenient detection of major cerebrovascular risk factors, including cerebral infarction, stroke, and aneurysms.
NeuFlow is a medical device that analyzes conventional 2D black-and-white MRA (Magnetic Resonance Angiography) images using 3D color imaging and data-driven insights, enabling a more accurate assessment of cerebrovascular health.
Certification Information:
FDA Clearance (510k): K240385
Korea MFDS Approval: No. 23-4077
NeuFlow is a medical device that analyzes conventional 2D black-and-white MRA (Magnetic Resonance Angiography) images using 3D color imaging and data-driven insights, enabling a more accurate assessment of cerebrovascular health.
Certification Information : FDA Clearance (510k): K240385
Korea MFDS Approval: No. 23-4077
Performs quantitative analysis of hemodynamic properties across the entire cerebrovascular system as well as specific vessels.
Supports efficient clinical workflows through full integration with existing hospital systems.
Enables accurate localization by overlaying 2D slices with 3D color vascular images.
Quantitative analysis of blood flow characteristics through Signal Intensity Gradient (SIG)
Providing Big Data–Driven Reports on
Cerebral Vessel Health
Delivers individualized cerebrovascular health management guidance powered by big data analytics.
Signal Intensity Gradient (SIG) is an FDA- and MFDS-approved indicator for analyzing blood flow characteristics, allowing for the quantitative assessment of cerebrovascular health.
Through a proprietary algorithm, conventional 2D black-and-white MRA images are transformed into 3D color representations, enabling intuitive visualization of blood flow characteristics.
NeuFlow is the only device to obtain FDA 510(k) clearance based on Substantial Equivalence.
Performs quantitative analysis of hemodynamic properties across the entire cerebrovascular system as well as specific vessels.
Supports efficient clinical workflows through full integration with existing hospital systems.
Enables accurate localization by overlaying 2D slices with 3D color vascular images.
Quantitative analysis of blood flow characteristics through Signal Intensity Gradient (SIG)
Providing Big Data–Driven Reports on
Cerebral Vessel Health
Delivers individualized cerebrovascular health management guidance powered by big data analytics.
01. Hemodynamic Data (SIG)
Signal Intensity Gradient (SIG) is an FDA- and MFDS-approved indicator for analyzing blood flow characteristics, allowing for the quantitative assessment of cerebrovascular health.
02. Three-dimensional vascular color mapping technology
Through a proprietary algorithm, conventional 2D black-and-white MRA images are transformed into 3D color representations, enabling intuitive visualization of blood flow characteristics.
03. FDA Approved
NeuFlow is the only device to obtain FDA 510(k) clearance based on Substantial Equivalence.
Moyamoya disease
Cerebral aneurysm
Cerebral infarction
Cerebral Small Vessel Disease
Hypertension
Diabetes
Hyperlipidemia
Obesity / Smoking
Forecasting the progression of Moyamoya disease
Reference : Impact of Endothelial Shear Stress on the Bilateral Progression of Unilateral Moyamoya Disease. Stroke. 2020
Forecasting outcomes in cerebral infarction
Reference : Cerebral artery signal intensity gradient from Time-of-Flight Magnetic Resonance Angiography and clinical outcome in lenticulostriate infarction. Front Neurol. 2023
Measuring the risk of cerebral aneurysm rupture
Reference : Geometric versus Hemodynamic Indexes for Rupture-Destined Aneurysms. Cerebrovasc Dis. 2024
MediImg Co., Ltd. | Est. 2018
Business License No. : 313-87-00931
Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea
R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park, Bundang, Gyeonggi-do, Korea
TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448
E-mail : info@mediimg.com
FDA 510K Approval Date : October 15, 2024
Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.
Approved by the MFDS
MediImg Co., Ltd. | Est. 2018
Business License No. : 313-87-00931
Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea
R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park,
Bundang, Gyeonggi-do, Korea
TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448 | E-mail|info@mediimg.com
FDA 510K Approval Date : October 15, 2024
Approved by the MFDS
Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.